Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Kivu Bioscience Inc.
ViroMissile, Inc.
MacroGenics
Avacta Life Sciences Ltd
Solve Therapeutics
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
University Health Network, Toronto
Blueprint Medicines Corporation
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Institut Bergonié
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
Baxter Healthcare Corporation
Agenus Inc.
Shanghai PerHum Therapeutics Co., Ltd.
Pfizer
Adaptimmune
Corvus Pharmaceuticals, Inc.
Sumitomo Pharma America, Inc.
Pfizer
Emory University
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
MacroGenics
Seagen Inc.
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Celgene
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Tocagen Inc.
Mie University
Merrimack Pharmaceuticals
Corcept Therapeutics
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
GlaxoSmithKline
National Institutes of Health Clinical Center (CC)
Shenzhen Second People's Hospital
Altor BioScience
Memorial Sloan Kettering Cancer Center
Valerio Therapeutics
Valerio Therapeutics
National Cancer Institute (NCI)
ImmunoFrontier, Inc.
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)